Johns Hopkins University

D&d Pharmatech Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Seulki Lee

Magdalena Scully

Martin Gilbert Pomper

Ted M Dawson

Valina L Dawson

Han Seok Ko

Seung Pil Yun

Pankaj Jay Pasricha

Eun Ji Park

Kang Choon Lee

Xiaoyuan Chen

Sung Kwon Lee

Won Bae Kim

Tae Hyung Kim

Jong-Sung Park

Yumin Oh

Maureen Horton

Lei Zhu

Ogyi Park

Magdalena Swierczewska

Pankaj J Pasricha

The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.

Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions

Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions

Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Compositions and methods for treating pancreatitis and pain with death receptor agonists

The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.

Ameliorating systemic sclerosis with death receptor agonists

Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.

Imaging agents for imaging protease activity and uses thereof

The present disclosure relates to an exendin-4 analog PEGylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analog can be increased via the selective PEGylation by using exendin-4 in which a cysteine is introduced into #40 site of the C-terminal, and treatment effect of medications can be increased, so that the exendin-4 analog can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion.

Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient

Disclosed herein are an N-terminal modified PEG-TRAIL conjugates and methods of making and using thereof. The PEG-TAIL conjugates have bioactivity that is substantially similar to that of native TRAIL coupled with an extended in vivo half-life and enhanced stability. The disclosed PEG-TRAIL conjugates exhibit significantly reduced hepatotoxicity when compared to that of non-PEGylated trimeric TRAIL. The disclosed methods of making the PEG-TRAIL conjugates provide a homogeneous, highly pure, form of N-terminal modified PEG-TRAIL. Compared to native TRAIL, the PEG-TRAIL conjugates exhibits high solubility and solution stability. The PEG-TRAIL conjugates are useful in preventing and treating proliferative or autoimmune diseases.

Methods of administering an N-terminal modified PEG-TRAIL

Growing community of inventors

Elkridge, MD, United States of America

Seulki Lee